Qrons Inc. (QRON)

[tutankhamuns]

OTC Markets Verified Profile 07/2019
https://www.otcmarkets.com/stock/QRON/profile

Description
The Company is an emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries (TBIs) and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100 an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200 an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company conducts its research in Israel under service agreements with Ariel University and has an ongoing Sponsored Research Agreement with Dartmouth College.

Company Officers & Contacts
Jacqueline Danforth
Compliance Officer

Service Providers
Network 1 Financial Securities
The Galleria Building, 2 Bridge Avenue
4th Floor
Red Bank, NJ 07701

Profile Data
Employees
7 as of 07/25/2019

$QRON

[tutankhamuns]

Float = 1,838,048
https://www.otcmarkets.com/stock/QRON/security

$QRON

[tutankhamuns]

$2.04 on the ask... Very thin after that. $QRON

[tutankhamuns]

6900 shares on the bid @ $1.45... $QRON

[tutankhamuns]

OTCX on the ask @ $1.88... $QRON

[tutankhamuns]

Information Disclosure Statement (IDS) Filed

07-02-2019

Application Number: 15/769349
https://portal.uspto.gov/pair/PublicPair

$QRON

[tutankhamuns]

Higher volume than usual today... $QRON

[tutankhamuns]

Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities

New York, NY, June 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (“TBIs”), including concussions and penetrating injuries, announced today the appointment of John N. Bonfiglio, PhD, MBA as its Chief Operating Officer.

Dr. Bonfiglio’s primary responsibility will be to oversee all investigational new drug (“IND”) activities in the United States in coordination with Qrons’ Israeli-based scientific team. Qrons’ goal is to accelerate the IND process in preparation for human clinical trials. The hiring of Dr. Bonfiglio represents another step in the Company’s strategy to strengthen its U.S. operations as it continues its regulatory approval efforts for its IND.

“I am pleased to be joining the team at Qrons. Traumatic brain injuries are a problem that is just now being recognized as a long-term chronic condition and for which there are currently no approved treatments. I believe that Qrons’ animal studies using state-of-the-art technology are very encouraging,” stated Dr. Bonfiglio.

Dr. Bonfiglio has held various C-suite positions with U.S. publicly traded biotech companies and he will actively assist the Company in expanding its U.S capital market activities. Dr. Bonfiglio received his BS in chemistry from State University of New York at Stony Brook, a master’s degree and PhD in synthetic organic chemistry from University of California at San Diego and an MBA from Pepperdine University.

Jonah Meer, Qrons’ Chief Executive Officer, commented, “With Dr. Bonfiglio’s appointment, we believe we now have in place in the U.S. the capability to obtain an IND for our QS100™ and QS 200™ product candidates, as well as other product candidates being developed in Israel. His experience in doing so is further augmented by his capabilities in dealing with the capital markets. The entire Qrons team is excited with John’s appointment.”

About Qrons Inc.

Headquartered in New York City, the Company is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussion. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel Scientific Innovations Ltd. a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

LINK: https://www.globenewswire.com/news-release/2019/06/27/1875308/0/en/Qrons-Appoints-Veteran-U-S-Based-Biotech-Executive-Dr-John-N-Bonfiglio-to-Lead-IND-and-Capital-Markets-Related-Activities.html

$QRON

[tutankhamuns]

Consistent 500 share blocks for months. Something’s setting up here. $QRON

[tutankhamuns]

CEO Meer is showing interest in Medicortex on LinkedIn.

Medicortex will be the first biomarker from a non-invasive sample of body fluid approved by regulatory agencies for the diagnosis or prognosis of TBI immediately after injury.
http://www.medicortex.fi/eng/technology-1/

This would directly complement one of Qrons’ products, QS200.



$QRON

[tutankhamuns]

The Ke Functional Materials Group @ Dartmouth College
http://www.keresearchgroup.com/group.html

$QRON

[tutankhamuns]

Compositions for regeneration and repair of neural tissue

US20180303974A1
United States

Inventor: Danny BARANES, Orly Eva WEISS, Eyal CHANJI, Liat Hammer, Tzachy MORAD, Ido MERFIELD

Current Assignee: Ariel University Research and Development Co Ltd

Worldwide applications
2016 WO EP US

Application US15/769,349 events
2015-11-03
Priority to US201562250017P
2016-11-03
Application filed by Ariel University Research and Development Co Ltd
2016-11-03
Priority to US15/769,349
2016-11-03
Priority to PCT/IL2016/051193
2018-05-04
Assigned to ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD.
2018-10-25
Publication of US20180303974A1
2019-05-28
Application status is Pending

$QRON

[tutankhamuns]

$1M offering with Network 1 Financial Services, Inc. filed AH

Sales commissions is 10% of the gross proceeds sold. Placement Agent will also receive a four-year warrant to purchase 10% of the shares sold at an exercise price of $2.50 per share and a 3% cash fee of the proceeds from the exercise of the warrants sold.
https://www.otcmarkets.com/filing/html?id=13445631&guid=SMJyUW68_wUvZ3h

$QRON

[tutankhamuns]

UCSF-Led Consortium Receives $26.2M to Develop Therapies for Traumatic Brain Injury

Experts Predict End to Decades-Long Deadlock in Drug Developments

A UC San Francisco-led consortium has received a $26.2 million award from the U.S. Army Medical Materiel Development Activity to develop treatments for traumatic brain injury. The Transforming Research and Clinical Knowledge in Traumatic Brain Injury Network, known as TRACK-TBI NET, will lead clinical trials of phase II drugs tested nationwide in 18 hospitals with Level 1 trauma centers.

“Over the course of decades, there have been more than 30 clinical trials for TBI, but to date no effective drugs have been identified,” said Geoffrey Manley, MD, PhD, principal investigator of TRACK-TBI and professor of neurosurgery in the UCSF Department of Neurological Surgery. “We hope that the new research will prove more fruitful than previous TBI studies that failed to distinguish patients by objective findings obtained from imaging or blood draws.”

The trials will match patients with a treatment according to findings on imaging, such as hemorrhage, brain bruising or neuro-inflammation, as well as the presence of blood-based biomarkers.

There were approximately 2.8 million TBI-associated hospitalizations, visits to emergency departments and deaths in 2013, according to the U.S. Centers for Disease Control and Prevention. Although many patients recover spontaneously from TBIs – which include concussions, regarded as mild TBIs – memory, movement, sensations and emotions may be impacted in the long term.

Earlier this year, UCSF researchers reported links between TBI and dementia, and TBI and Parkinson’s disease.

Awareness of TBI has focused on athletes and those in the armed forces, noted Manley, who is also chief of neurosurgery at Zuckerberg San Francisco General Hospital and Trauma Center, and a member of the UCSF Weill Institute for Neurosciences. In fact, the condition is prevalent across all populations, due to falls and motor vehicle accidents, with the fastest-growing incidence among those over the age of 75.

“We are entering a new era of precision medicine in the research and treatment of TBI,” Manley said. “Using novel and developing tools in the fields of imaging, biomarkers and genomics, we are better able to diagnose patients and test treatments to relieve the substantial burden that patients carry for life.”

TRACK-TBI has built a network of 3,000 patients whose diagnoses cover the spectrum of mild-to-severe TBI, and developed a standardized approach to analyze imaging, clinical data, biospecimens and treatment outcomes across research sites. Additionally, its databases include what may be the world’s largest serial collection of brain scans and biospecimens of TBI patients.

The U.S. Department of Defense award will be administered by the Medical Technology Enterprise Consortium over a five-year period.

LINK: https://www.ucsf.edu/news/2018/10/412001/ucsf-led-consortium-receives-262m-develop-therapies-traumatic-brain-injury

$QRON

[tutankhamuns]

“Drug Treatment for Traumatic Brain Injury (DTTBI)”

Solicitation Overview
https://mtec-sc.org/dttbi/
Project Award: $26.2M

Request for Project Proposals
https://mtec-sc.org/wp-content/uploads/2018/03/Amendment-01_DTTBI_MTEC_RPP_Final_26Mar2018_Public-SIte.pdf

$QRON

[tutankhamuns]

$QRON - Member of the Medical Technology Enterprise Consortium (MTEC) and listed as a Non-Traditional Government Contractor
https://mtec-sc.org/current-members/

Traditional vs. Nontraditional Defense Contractor
https://mtec-sc.org/wp-content/uploads/2016/12/University_TraditionalvsNontraditional.pdf

$QRON

[tutankhamuns]

New MM GTSM on the bid... $QRON

[tutankhamuns]

To date, we have identified two product candidates. We have completed an in-vivo efficacy experiment with QS100TM for treating penetrating brain injuries in an animal model that was successful in substantiating our theories and practices regarding cell regeneration. We have begun animal in-vivo efficacy experiments with QS200TM for treating concussions and other diffused axonal injuries.

In the next 12 months, we currently plan on completing development of our product candidates. This will require us to continue working with Dartmouth under the Sponsored Research Agreement in our development of innovative 3D printable biocompatible advanced materials and stem cell delivery techniques. At our research facilities located in Ariel's labs our Stem Cells Team will continue development of our proprietary, neuro-regenerative MSC lines. Upon completion of the development of our product candidates we will begin testing for efficacy. This will require us to establish an Efficacy Team, in preparation to reach clinical trials.
https://www.otcmarkets.com/filing/html?id=13427529&guid=mW2yUq67duvo33h

$QRON

[tutankhamuns]

Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations

New York, NY, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries, announced today the appointment of Dr. Motti Ratmansky, a member of Qrons’ Scientific Advisory Board as Special Advisor to the Company for IND & Clinical Trials. Remaining on the Scientific Advisory Board, Dr. Ratmansky will take a more active role as Senior Advisor to assist the Company in preparing for its IND (“Investigational New Drug”) filing. This represents the Company’s further steps to enhance its operation for its IND and clinical trial enabling process, including the possible addition of US-based individuals.

Jonah Meer, Qrons Chief Executive Officer, commented, “Dr. Ratmansky is a highly experienced, well esteemed doctor. We have benefited from his guidance during his time on our Advisory Board. As we have been developing our QS100™ and QS 200™ product candidates there is now a need for the focus of a highly qualified person to advise us as we begin to prepare for dealing with the FDA IND program and clinical trials. Dr. Ratmansky is that person!”

Dr. Ratmansky is a qualified good clinical practice researcher and a member of Loewenstein's Hospital Institutional Review Board (IRB), with vast experience in human clinical studies design, regulatory approval and ethical aspects. He is also a member of the hospital's research funding committee, evaluating the financial aspects of clinical trials design. Loewenstein Hospital is the largest and leading Israeli hospital in the field of rehabilitation medicine.

As a clinical trial lead investigator, he is responsible for preparing applications to the local IRB and U.S. National Institute of Health (NIH) National Library of Medicine registration, outlining the proposed clinical study and patients consent forms. He is currently serving as a lead investigator in 12 clinical trials.

As a medical consultant in recent years to early stage biotech companies, he maintains the linkage between the R&D and the regulatory strategy by interacting with FDA regulatory consultants' designing research plans in accordance with regulatory demands. He has published several original research papers and reviews in international peer reviewed medical journals.

Dr. Ratmansky holds an M.D. degree from the Technion Institute and B. Med.Sc from The Hebrew University as well as two specialties both in pain and rehabilitation medicine with 20 years of experience in clinical medicine.

Ido Merfeld, Qrons co-Founder and Head of Product, stated, “I have had the privilege of working with Dr. Ratmansky on our Scientific Advisory Board. We are thrilled that he sees the promise of our products and has agreed to provide special assistance and focus as we begin preparing for an IND and clinical trials.”

Dr. Ratmansky: “I’ve had the pleasure of working with Ido and the Qrons team as a member of the Scientific Advisory Board for the last year and a half and have seen first-hand the revolutionary treatment they are developing for TBI. I am excited to provide special assistance to shepherd the product candidates to an IND filing and clinical trials.”

About Qrons Inc.

Headquartered in New York City, the Company is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussion. The Company has two candidate products for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

$QRON

[tutankhamuns]

MMs are filling hidden bids at $1.30... $QRON

[tutankhamuns]

Nice 10K bid @ $1.20... $QRON

[tutankhamuns]

Qrons Announces Filing of PCT Patent -- Techniques for Promoting Neuronal Recovery

NEW YORK, NY, April 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries, announced today that its PCT (“Patent Cooperation Treaty”) patent application, “Techniques for Promoting Neuronal Recovery”, relating to the treatment of traumatic injury to the central nervous system, such as TBI was filed on April 7, 2019 (Application No. PCT/IB2019/052850).

This PCT application, filed with the World Intellectual Property Organization, allows Qrons to file patent applications and seek protection in most major market countries throughout the world. These patent applications, if granted, have the potential to provide protection for Qrons’ technology for 20 years - until at least 2039.

The PCT application relates in general to the treatment of pathological central nervous system conditions, such as traumatic injury or neurodegenerative disease. More specifically the application includes several hundred claims relating to the uses of hydrogels in the treatment of such conditions.

Jonah Meer, Qrons Chief Executive Officer, commented, “We believe that the filing of this PCT patent application is a significant step in being able to protect our innovative and novel TBI therapy for many years to come. It is particularly important as we get closer to preparing for clinical trials of our product candidates in patients suffering from TBIs. In addition to TBIs, our technology also gives us opportunities to develop unique therapies for other forms of neuronal injuries.”

The PCT patent application originated from a provisional patent application by the same title that was filed with the U.S. Patent and Trademark Office (USPTO) on April 9, 2018 and a provisional patent application by the same title that was filed with the USPTO on January 22, 2019.

Ido Merfeld, Qrons co-founder and Head of Product and inventor, stated, “The filing protects our invention of implanting a synthetic hydrogel in order to promote neurogenesis and/or inhibit astrogliosis. We believe that the invention may have broad applications beyond TBIs to include many central nervous system conditions, including glioma, stroke, Parkinson’s, Alzheimer’s and Huntington’s disease as well as other neurodegenerative disorders.”

About Qrons Inc.

Headquartered in New York City, the Company is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussion. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

LINK: https://www.globenewswire.com/news-release/2019/04/17/1805472/0/en/Qrons-Announces-Filing-of-PCT-Patent-Techniques-for-Promoting-Neuronal-Recovery.html

[tutankhamuns]

Dr. Gadi Turgeman finished his undergraduate studies (B.Med.Sc.) in the faculty of dental medicine in the Hebrew university in 1995. As an excellent student he was accepted for the prestigious double degree program of the HebrewUniversity, and graduating six years later both D.M.D. and Ph.D. degrees. His main focus in his graduate study was on the application of bone marrow mesenchymal stem cells for skeletal regeneration and tissue engineering. Dr. Turgeman continued his training in the Hebrew University further specializing in MSCs molecular biology, genetic engineering and differentiation.

During 2001 to 2005 Dr. Turgeman served as a medical officer in the IDF. In 2005 Dr. Turgeman accepted a Lecturer position in the Department of molecular biology in Ariel University Center of Samaria and in 2011 he was promoted to the rank of senior lecturer and in 2014 was appointed as the head of the department for pre-medical studies. Dr. Turgeman guides 2 Ph.D. students and 1 M.Sc. students in his lab.

His main research interests include:

1. Mesenchymal stem cells and their therapeutic potential in neurobehavioral diseases

2. Neurogenesis and behaviour

3. The interaction between cancer cells/cancer stem cells and mesenchymal stem cells.

Dr. Turgeman has published more then 20 research articles and registered several patents and patent applications.
http://www.ariel.ac.il/sites/gadit

The Stem Cell Research Lab
http://www.ariel.ac.il/sites/gadit/stem-cell-research-lab

Publications
http://www.ariel.ac.il/sites/gadit/listpublications

$QRON

[tutankhamuns]

Volume has been very consistent since the February news release... $QRON

[tutankhamuns]

Bringing Neurodegenerative Disease Research into the Minds of Investors

https://wearecomet.com/projects/qrons/

$QRON

[tutankhamuns]

Solid 10-K hit AH. Still under the radar... $QRON

[tutankhamuns]

Expecting news on QS200 and new equity investments to help meet uplisting requirements. $QRON

[tutankhamuns]

This will easily trade between $20-$30/share once it debuts on a major stock exchange. This kind of technology does not currently exist anywhere else in the world. $QRON

[tutankhamuns]

Big news coming here. That’s why they commenced the uplisting process. IMO $QRON

[tutankhamuns]

Qrons Retains Investment Banking Firm Network1 Financial Securities Inc.

Mandate includes Advisory, Capital Raising and Uplisting Guidance

MIAMI, FL / ACCESSWIRE / February 21, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel- based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), both concussions and penetrating injuries , announced today that it has retained investment banking firm Network1 Securities Inc. ("Network1") as its Capital Markets Advisory and Investment Banking firm.

Network1 will act as Qrons' Advisor and Banker in connection with the overall management of its recent OTC listing, including the functions of capital raising, investor management, and guidance and support for a possible uplisting to a major exchange when appropriate.

Jonah Meer, CEO of Qrons, stated, "We chose Network1 based on its demonstrated expertise and success in helping early stage life science companies move through their growth stages from a capital markets perspective, and attain listing on a national exchange".

"We are very pleased to have been chosen for this assignment," said Robert Giordano, Managing Director of Investment Banking for Network1 Financial Securities Inc. "Their novel stem cell-based technology has the potential to effectuate breakthrough therapeutic solutions for both concussions and penetrating TBIs, and this potential, as well as the Company's intent to secure a listing on a national exchange as soon as possible are essential criteria in our selection process of emerging life science companies to engage with."

About Qrons Inc.

Headquartered in Miami, Florida, the Company is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussion. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company

received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

About Network1 Financial Securities Inc.

Registered with FINRA since 1983, Network1 has its corporate headquarters in Red Bank New Jersey, its institutional placement office in downtown Manhattan and several retail distribution offices in and around the metropolitan New York area. It provides a full complement of services to institution/retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. More specifically it has successfully completed a number of NASDAQ based IPO's which in many cases have included a private placement prior to the IPO. For more information, please visit: http://www.network1.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

The OTC Markets Inc has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

CONTACT:

For the Company
Qrons Inc.
CEO
917 282 5032

For Network 1
Robert Giordano
Managing Director-Investment Banking
732-673-7044

SOURCE: Qrons Inc.



View source version on accesswire.com:
https://www.accesswire.com/536276/Qrons-Retains-Investment-Banking-Firm-Network1-Financial-Securities-Inc

[tutankhamuns]

Up 78.3% today. Very nice. $QRON

[tutankhamuns]

Wait until this company releases more news about their patented technology... $QRON

[tutankhamuns]

Accumulation in the $.70-$1.00 range after very promising news. New highs in short order. IMO $QRON

[tutankhamuns]

Some new short interest here suddenly. Volume doesn’t indicate any substantial dilution. How low will they take it is the question... $QRON

[tutankhamuns]

Qrons Completes Successful In-Vivo Experiment with its QS100 Candidate Product for Treating Penetrating Brain Injuries in an Animal Model

Detailed experimental results were filed in a second provisional patent application for "Techniques for Promoting Neuronal Recovery."

Preparing for animal In-vivo efficacy experiments with its QS200™ Candidate Product for treating Concussions and other Diffused Axonal Injuries.

MIAMI, FL / ACCESSWIRE / January 30, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons "or the "Company"), a preclinical biotechnology company developing advanced stem cell-synthetic hydrogel based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it had reached a milestone with the development of its two candidate products, QS100™ for treating penetrating brain injuries and QS200™, for treating concussions and other diffused axonal Injuries.

Both QS100™ and QS200™ integrate proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100™ is an injury specific, 3D printable, implantable MSCs-synthetic compound, to treat penetrating brain injuries (such as gunshot wounds, motor vehicle accidents and falls) and QS200™ is an injectable MSCs-synthetic compound for the treatment of diffused injuries commonly referred to as concussions.QS100™ has demonstrated astrogliosis inhibition and induction of neuronal differentiation in in-vivo animal experiments while QS200™ research was expedited and is near completion with further pre-clinical experiments scheduled to determine its efficacy for concussions and diffused brain injuries.

The Company believes that its latest advances provide a superior stem cells/synthetic hydrogel integration which will enable the precise, effective and controlled delivery of Qrons' proprietary modified stem cells.

As a result of its on-going research, the Company has filed a second provisional application for its patent - Techniques for Promoting Neuronal Recovery which was filed in April 2018 and includes further technological developments and data. The Company is working on filing additional patent applications to protect its intellectual property.

Ido Merfeld, co-founder and Head of Product stated "We have substantiated our previous pre-clinical studies with further in-vivo animal experiments. The foundation of our science has further led us to expedite the completion of the development of QS200™, our candidate product to treat concussions. We are excited to be able to unleash the potential of our candidate products to a broader spectrum of traumatic brain injuries in the future".

Jonah Meer, co-founder and CEO remarked, "I am proud of the scientific achievements to date. We believe that the advances our researchers have made provide hope to those suffering a TBI and that our QS200™ candidate product will provide solutions to deal with concussions and various other forms of TBI.

About Qrons Inc.

Headquartered in Miami, Florida, the Company is a publicly traded preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could potentially treat a wide range of neuro-degenerative diseases. The Company has 2 candidate products for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

Safe Harbor Statement

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future product development plans, other statements regarding future research, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company's filings with theSecurities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Jonah Meer
212-945-2080
Email: [e-mail]

SOURCE: Qrons Inc.



View source version on accesswire.com:
https://www.accesswire.com/533953/Qrons-Completes-Successful-In-Vivo-Experiment-with-its-QS100-Candidate-Product-for-Treating-Penetrating-Brain-Injuries-in-an-Animal-Model

[tutankhamuns]

This stock was sitting at $2 for nearly an entire year before company insiders exercised their options. Rather peculiar that it’s now sitting below strike price. $QRON

[tutankhamuns]

Low liquidity for the moment, but that will change once the market starts to hear “clinical trials” and “FDA” $QRON

[tutankhamuns]

Seth Farbman Interviews Jonah Meer, CEO of Qrons, Inc.

[tutankhamuns]

OTCX top bid and top ask. Clear manipulation now. News must be coming soon. IMO $QRON

[tutankhamuns]

First block of shares sold at ~$1 in a very long time. Company directors are exercising options at $2/share. $QRON

[tutankhamuns]

I can’t wait to see the first prototype this year. Probably the most interesting company I’ve ever researched. $QRON

[tutankhamuns]

MMs aren’t selling shares below $2. $QRON

[tutankhamuns]

OTCX bidding $2.30 $QRON

[tutankhamuns]

Added $2.00

[tutankhamuns]

Interesting loading going on here... $QRON

[tutankhamuns]

Qrons Extends Services Agreement with Ariel University for Additional Year
Agreement Will Facilitate Completion of First Candidate Product to Treat Traumatic Brain Injuries

MIAMI, FL / ACCESSWIRE / December 17, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it has renewed its Services Agreement with Ariel University for an additional year. This will allow Qrons to carry out the development of its modified mesenchymal stem cells ('MSCs") lines and supply models to aid in the treatment of TBI.

The Agreement contains the same terms and conditions as the expiring Agreement.

Jonah Meer, CEO of Qrons noted "We are pleased to renew our relationship with Ariel for a third year and are appreciative of the services provided. Our scientists are pleased with the progress made toward developing our first candidate product. Together with the Sponsored Research Project at Dartmouth College, we believe we are on track to have our first candidate product delivered next year. Following delivery, we will take the necessary preparatory steps to enable us to enter into clinical trials. We believe our solution stands out as our goal is to effectively heal the patient from the devastating consequences of TBI, a huge unmet medical need. Healing the patient will serve to avoid long-term treatment, degradation of the quality of life, possible future neuro-degenerative diseases and the substantial costs associated with TBI."

About Qrons Inc.

Headquartered in Miami, Florida, the Company is a publicly traded preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could potentially treat a wide range of neurodegenerative diseases. The Company's treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable implant, smart materials, and a novel delivery system. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials and stem cell delivery techniques to treat TBI. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

About Ariel University

Ariel University ('AU") is one of Israel's most respected institutions. AU has 23 research centers, including an Integrative Brain Science Center and a world-renowned Material Research Center.

AU has signed academic cooperation agreements with over 51 higher education institutions around the world, including the United States, Russia, France, Germany, Brazil, Portugal, Costa Rica, Ecuador, Argentina, Turkey, Poland, Ukraine, Georgia, Kazakhstan, Taiwan, and Armenia.

AU’s Molecular Biology Department which has been operating independently since 2003 has a wide variety of laboratory courses in which students apply the theoretical knowledge they have acquired.

Safe Harbor Statement

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future product development plans, other statements regarding future research, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties, and assumptions that could cause the Company's actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Jonah Meer 786-620-2410
Email: [e-mail]

SOURCE: Qrons Inc.



View source version on accesswire.com:
https://www.accesswire.com/530539/Qrons-Extends-Services-Agreement-with-Ariel-University-for-Additional-Year


Read more: http://m.digitaljournal.com/pr/4073624#ixzz5a4x7rzf2

[tutankhamuns]

The float is around 2M. $QRON

[tutankhamuns]

Our proprietary, engineered mesenchymal stem cells act like living pharmacies, continuously delivering neuro-protective and neuro-regenerative agents to affected areas. We believe this combination will minimize neuronal loss and ultimately help patients regain or improve function.

This is so intriguing to me.

[tutankhamuns]

This stock should do very well going into 2019. Product prototype TBA and preparation for clinical trials. $QRON

[tutankhamuns]

https://qrons.com/approach/